Easywell Biomedicals (Taiwan) Performance
| 1799 Stock | TWD 67.80 1.20 1.80% |
The firm shows a Beta (market volatility) of 0.64, which means possible diversification benefits within a given portfolio. As returns on the market increase, Easywell Biomedicals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Easywell Biomedicals is expected to be smaller as well. At this point, Easywell Biomedicals has a negative expected return of -1.63%. Please make sure to confirm Easywell Biomedicals' jensen alpha, treynor ratio, value at risk, as well as the relationship between the total risk alpha and maximum drawdown , to decide if Easywell Biomedicals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Easywell Biomedicals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
Easywell |
Easywell Biomedicals Relative Risk vs. Return Landscape
If you would invest 20,600 in Easywell Biomedicals on September 5, 2024 and sell it today you would lose (13,820) from holding Easywell Biomedicals or give up 67.09% of portfolio value over 90 days. Easywell Biomedicals is generating negative expected returns and assumes 4.8961% volatility on return distribution over the 90 days horizon. Simply put, 43% of stocks are less volatile than Easywell, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Easywell Biomedicals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Easywell Biomedicals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Easywell Biomedicals, and traders can use it to determine the average amount a Easywell Biomedicals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3327
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 1799 |
Estimated Market Risk
| 4.9 actual daily | 43 57% of assets are more volatile |
Expected Return
| -1.63 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.33 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Easywell Biomedicals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Easywell Biomedicals by adding Easywell Biomedicals to a well-diversified portfolio.
Easywell Biomedicals Fundamentals Growth
Easywell Stock prices reflect investors' perceptions of the future prospects and financial health of Easywell Biomedicals, and Easywell Biomedicals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Easywell Stock performance.
| EBITDA | (140.2 M) | |||
| Cash And Equivalents | 399.51 M | |||
| Cash Per Share | 3.49 X | |||
| Total Debt | 344.06 M | |||
| Debt To Equity | 0.41 % | |||
| Book Value Per Share | 7.01 X | |||
| Cash Flow From Operations | (102.55 M) | |||
| Earnings Per Share | (1.31) X | |||
About Easywell Biomedicals Performance
Evaluating Easywell Biomedicals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Easywell Biomedicals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Easywell Biomedicals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Easywell Biomedicals, Inc., a biopharmaceutical and medical device company, develops and commercializes medical devices, drug substances, and pharmaceutical dosage forms in Taiwan and internationally. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan. EASYWELL BIOMEDICAL operates under Medical Devices classification in Taiwan and is traded on Taiwan OTC Exchange.Things to note about Easywell Biomedicals performance evaluation
Checking the ongoing alerts about Easywell Biomedicals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Easywell Biomedicals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Easywell Biomedicals generated a negative expected return over the last 90 days | |
| Easywell Biomedicals has high historical volatility and very poor performance | |
| Net Loss for the year was (183.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Easywell Biomedicals has accumulated about 399.51 M in cash with (102.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.49. |
- Analyzing Easywell Biomedicals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Easywell Biomedicals' stock is overvalued or undervalued compared to its peers.
- Examining Easywell Biomedicals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Easywell Biomedicals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Easywell Biomedicals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Easywell Biomedicals' stock. These opinions can provide insight into Easywell Biomedicals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Easywell Stock Analysis
When running Easywell Biomedicals' price analysis, check to measure Easywell Biomedicals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Easywell Biomedicals is operating at the current time. Most of Easywell Biomedicals' value examination focuses on studying past and present price action to predict the probability of Easywell Biomedicals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Easywell Biomedicals' price. Additionally, you may evaluate how the addition of Easywell Biomedicals to your portfolios can decrease your overall portfolio volatility.